Market Overview Invasive fungal infection (IFI) is one of the most common nosocomial infections and may result in invasive diseases in patients with various underlying diseases or other host factors.
Market Dynamics Increasing advanced and diverse technologies to explore emerging fungal pathogens are expected to drive the market growth.
According to the American Society For Microbiology, published on 06 October 2020, infectious fungal agents include previously unidentified or rare pathogens that can cause unprecedented casualties in biodiversity, food security, and human health.
Human activity influences, including the climate change crisis and globalized transport, are underlying factors shaping fungal adaptation to increased temperature and expanded geographical regions. Moreover, the emergence of novel antifungal-resistant strains linked to excessive antifungals (in the clinic) offers an additional challenge to control dangerous fungal outbreaks.
Therefore, the alarming frequency of fungal infections in medical requires effective research to understand the virulent nature of fungal pathogens and improve infection in susceptible hosts. Mycology-driven research has benefited from a contemporary and combined approach to omics technology, deepening the biological, biochemical, and biophysical understanding of these emerging fungal pathogens.
For instance, the emergence of new fungal pathogens has unfolded in parallel with the genomic sequencing revolution, providing tools to help broaden the evolutionary knowledge of these pathogens' virulence, host range, and geographic expansion.
Current approaches for genomic analysis include assembling a genome de novo for a novel species and resequencing using a complete reference genome to identify variants through comparisons. Multiple methods for assembly and resequencing are available, including short-read sequence technology (e.g., Illumina) and long-read technology beneficial for a repetitive genome (e.g., Pacific Biosciences and Oxford Nanopore).
By capitalizing on such advancements in genomics technology, crucial information about the genome composition of rapidly emerging fungal species reveals gene family expansions and gene loss events, which outlines their functional potential for virulence and host infection. Thus, from the above statements, the market is expected to drive in the forecast period.
Market Segmentation Global Invasive Fungal Infection Market – By Disease Type • Candidaemia and invasive Candiasis • Intra-abdominal Candiasis • Cryptococcal Meningitis • Esophageal candidiasis • Histoplasmosis acute pulmonary • Invasive Aspergillosis • Invasive Rhinosinusitis • Mucormycosis • Others Global Invasive Fungal Infection Market – By Drug Type • Polyenes • Triazoles • Echinocandins • Flucytosine • Others Global Invasive Fungal Infection Market - By Region • North America • South America • Europe • Asia Pacific • Middle East & Africa
Competitive Landscape Major key players for invasive fungal infection market are Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abbott, Merck & Co., Astellas Pharma Inc. and Scynexis Inc . The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the invasive fungal infection market globally.
For instance, SCYNEXIS, on September 22, 2021, announced the U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the first new antifungal class of therapy approved by the U.S. FDA for vaginal yeast infections in more than 20 years.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
